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Abstract Attention deficit hyperactivity disorder (ADHD)
impacts significantly on the quality of life (QoL) of patients
and their families. Choice of therapy is increasingly influ-
enced by treatment satisfaction and patient preference, with
once-daily modified-release methylphenidate (MPH-MR)
formulations offering clear benefits compared with imme-
diate-release (IR) dosage forms. The effects of MPH-MR on
QoL in ADHD have not been widely investigated and need
more clarity in practice. The open-label OBSEER study
evaluated the effectiveness and tolerability of Equasym
XL, a MPH-MR formulation, in routine practice. Children
and adolescents (aged 6–17 years) with ADHD and
attending school were included if Equasym XL treatment
was planned by the treating physician. Physicians, parents
and patients completed questionnaires assessing QoL
(KINDL; parent, child or adolescent versions), satisfaction
with medication, adherence and treatment tolerability at
baseline (Visit 1), 1–3 weeks (Visit 2) and 6–12 weeks
(Visit 3) over a maximum 3-month observation period. Data
from 822 consecutively referred patients were analysed.
QoL and medication satisfaction increased from Visit 1 to
Visit 3, with both patients and parents rating therapy with
Equasym XL as better than previous drug therapy. KINDL
total score effect sizes were 0.67 (parents’ ratings), 0.52
(children’s ratings) and 0.51 (adolescents’ ratings; all
p \ 0.001). All KINDL subscores also increased: both
parents and patients had the greatest improvement for
school. Adherence to Equasym XLwas frequently rated as
superior to prior treatment, particularly compared with
MPH-IR repeated dosing. Treatment was generally well
tolerated; approximately 3% of the patients discontinued
treatment due to adverse events. Equasym XL improved
QoL compared with prior therapy, and resulted in good
medication satisfaction and adherence in drug-naı¨ve and
previously treated patients.
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Introduction
Quality of life (QoL) has become an increasingly important
outcome in child mental health clinical research [10, 11,
14], and it has long been recognised that a diagnosis of
attention deficit hyperactivity disorder (ADHD) can result
in broad impairments of QoL in patients and their families
[24, 26]. QoL in ADHD is influenced by numerous factors
[35], including physical, psychological, cognitive and
social aspects of wellbeing and function [14].
ADHD can have a significant impact on a patient’s
perception of their QoL. Everyday activities such as school
and homework, family routines and playing with other
children may be affected, as well as relationships with
family members and peers [12]. QoL in patients with
ADHD has been shown to be considerably lower than
community norms [34], and studies show that patients with
ADHD experience QoL deficits comparable with those in
other chronic diseases, such as asthma, cancer and cerebral
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palsy [17, 38]. ADHD has also been shown to impact
negatively on parents’ QoL and emotional health, and
presents a burden on the family as a whole [12]. Difficulties
that families of children with ADHD may experience
include strained family relationships, parenting distress and
worry, depression, higher incidences of divorce and sepa-
ration, and possible effects on work status and productivity
[12, 22].
Improvement of patient QoL is regarded as an important
treatment goal [7]. It is thought that treatments that can
provide effective symptom control in ADHD may also
have the potential to improve patients’ overall QoL [4].
Methylphenidate (MPH) is recognised as the first-line
choice of medication for reducing ADHD symptoms in
children and adolescents [4]. However, the effect of MPH
treatment on the everyday functioning and wellbeing of
children and adolescents with ADHD has not been well
studied to date. An open-label study showed that QoL
scores improved along with symptoms during 3-month
MPH therapy, suggesting that such effects could be sec-
ondary to effects on the core features of ADHD [21].
Consistent with this, a study that had an open-label dose
optimisation phase followed by a randomised, placebo-
controlled, double-blind classroom phase demonstrated
that MPH therapy was associated with a robust improve-
ment in child and family health-related QoL [27]. Further
analyses of the study showed that the improvement in QoL
was linked to improvements in both ADHD symptoms and
medication satisfaction, with patient satisfaction as a strong
predictor of initial changes in QoL as symptom improve-
ment [18]. There is also some evidence from this and
another study that family QoL measures are improved by
MPH treatment [7, 18]. The development of specialised
tools (for example the Global Impression of Perceived
Difficulties [GIPD] scale, the Life Participation Scale
[LPS] and the Kinder Lebensqualita¨tsfragebogen [KINDL]
questionnaire [31, 37, 39]) allows the opportunity to
measure the QoL of children and adolescents with ADHD,
and their response to treatment, comprehensively.
Treatment satisfaction and patient/parent preference are
increasingly important determinants of the success of
clinical care in ADHD [20]. Improved patient satisfaction
may result in better outcomes through greater adherence to
therapy [8]. Parents are often asked how satisfied they are
with ADHD medication in clinical trials [5], and generally
show higher rates of satisfaction than their children, par-
ticularly in the treatment of ADHD [16]. Multiple dosing
can be problematic, as it can cause adherence issues and
complications related to privacy, stigmatisation by class-
mates, potential abuse and accountability of the school
administration [23]. By eliminating the need for multiple
daily dosing, the introduction of once-daily, long-acting
medication has improved the convenience of ADHD
treatment, with potential for greater satisfaction for both
patients and their parents.
The OBSEER (OBservation of Safety and Effectiveness
of Equasym XL in Routine care) study was an observa-
tional, non-controlled, non-interventional, post-marketing
surveillance study conducted in Germany, which examined
changes in effectiveness and safety outcomes over 3 months
in patients with ADHD receiving once-daily Equasym XL1
(Shire Pharmaceuticals Ireland Limited, Ireland) [15]. In
this paper, we present a longitudinal assessment of QoL and
medication satisfaction, including adherence and tolerabil-
ity, in patients enrolled in the OBSEER study.
Methods
Study design
The open-label, prospective, multicentre, observational,
post-marketing OBSEER study was designed primarily to
assess the effectiveness and safety, and is described in full
elsewhere [15]. Here, pre-specified outcomes related to
QoL and satisfaction with therapy are examined.
Patients and treatment
Patients with ADHD (diagnosed according to the Diagnostic
and Statistical Manual of Mental Disorders, Fourth Edition,
Text Revision [DSM]-IV-TR [2] or the International Clas-
sification of Diseases [ICD]-10 criteria [40]) aged
6–17 years and attending school were included if treatment
with Equasym XL was planned by the treating physician.
Patients were included whether or not they had received
Equasym XL or other treatment prior to the study.
Treatment with once-daily Equasym XL was adminis-
tered according to standard practice under the therapeutic
responsibility of the attending physician; ethics or institu-
tional review board approval was not required for this study.
Written informed consent was obtained from parents.
Assessments
Health-related QoL
QoL was assessed using the KINDL questionnaire for
the assessment of health-related QoL in childhood and
1 Equasym XL is the UK trade name, and is registered and marketed
by Shire in the following countries under the following trademarks:
Denmark, Equasym Depot; Finland, Equasym Retard; France,
Quasym LP; Germany, Equasym Retard; Ireland, Equasym XL;
Netherlands, Equasym XL; Norway, Equasym Depot; Sweden,
Equasym Depot; South Korea, Metadate CD; Mexico, Metadate
CD. Information correct at August 2011.
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adolescence [31]. This is a short, validated tool comprising
24 items, with six subscores (physical wellbeing, emotional
wellbeing, self-esteem, family, friends and school). Three
different versions were used according to the age group:
KID-KINDL was used for children aged 6–11 years old;
the self-reported KIDDO-KINDL for adolescents aged
12–17 years old; and KINDL for parents of patients aged
6–17 years old. Scores were transformed such that the
range of possible values for the sub-scores and the total
score was from 0 (most negative state) to 100 (most
positive state).
Treatment satisfaction
Treatment satisfaction was evaluated using the Satisfaction
with Medication scale (SAMS), a newly designed tool that
consists of 12 items (including an item for global satis-
faction with medication) scored on a six-point scale, with
low values indicating positive attitudes to drug therapy, and
high values indicating negative attitudes. The parent report
form of the SAMS (SAMS-P) assessed parents’ satisfaction
with medication, while the self-report form (SAMS-S)
assessed patient satisfaction with medication. The total
score of each rating scale is the sum of the item divided by
the number of items, and ranged from 1 to 6. The devel-
opment of the SAMS tool is described in a companion
paper [20].
Physician-rated adherence and tolerability
Adherence to treatment was graded on a scale between 1
and 6 (where 1 = excellent [very good] and 6 = failed
[inadequate]) by the treating physician. Treatment tolera-
bility was assessed by the treating physician as ‘very good’,
‘good’, ‘moderate’ and or ‘poor’.
Assessment timings
The planned observation period for each patient was
6–12 weeks after first use of Equasym XL. Three visits
were planned: Visit 1, baseline visit and initiation of
Equasym XL treatment; Visit 2, follow-up visit scheduled
for 1–3 weeks after first use of Equasym XL; Visit 3, final
visit 6–12 weeks after first use of Equasym XL. The
attending physician assessed adherence at each visit, and
global tolerability at Visit 3. Patients and parents assessed
satisfaction with medication at each visit, and QoL at Visit
1 and Visit 3.
Statistical analyses
The following outcomes were assessed: parent-rated sat-
isfaction with therapy and perception of patient’s QoL by
visit and as change from baseline; patient-rated satisfaction
with therapy and QoL by visit and as change from baseline;
physician-rated tolerability and adherence.
Results presented are for the intent-to-treat population.
All statistical analyses were performed post-hoc. Paired
t tests were used for the analyses of KINDL scores, and
multivariate analysis of variance for the analyses of SAMS
scores; effect sizes [28, 36] were calculated using Cohen’s
d [13]. In subgroup analyses, patients were assigned to
groups according to their treatment prior to starting Equ-
asym XL (no treatment; or treatment with MPH modified
release (MR), MPH immediate release (IR) administered
once daily, MPH-IR administered several times per day, or
‘other’, where treatment was unspecified (atomoxetine,
amphetamine or insufficiently specified).
Results
Study population
In total, 852 patients were registered for the study. Thirty
patients were excluded from the analysis due to invalid
data; therefore, 822 patients were included in the safety
analysis population. Baseline demographics for the total
population are described elsewhere [15].
Six hundred and fourteen patients had received prior
treatment for ADHD, while 208 patients were treatment-
naı¨ve; baseline characteristics by prior treatment group are
shown in Table 1. The mean (standard deviation [SD])
timing for Visit 3 was 10.1 (4.0) weeks after the first use of
Equasym XL.
Health-related quality of life
On an average, the parent-rated KINDL total score was 62.8
points at Visit 1 and 71.1 points at Visit 3, indicating a 13.3%
improvement in QoL on treatment with Equasym XL,
which was significant (p \ 0.001; Table 2). Descriptively,
the greatest improvement was for the sub-score school,
which increased by 11.1 points, and the smallest improve-
ment was for the sub-score physical wellbeing, which
increased by 6.9 points. Similarly, the patient-rated KID-
KINDL (6–11 years) total score averaged 66.3 points at
Visit 1 and 73.4 points at Visit 3, indicating an improvement
in QoL across all subscales with Equasym XL which was
significant (p \ 0.001; Table 2). The greatest improvement
in the KID-KINDL was for school, which increased by 11.1
points, while the smallest improvement was for physical
wellbeing, which increased by 4.9 points. Effect sizes of
parent ratings (Cohen’s d = 0.37–0.67) and patient ratings
(Cohen’s d = 0.22–0.54) were all in the small-to-moderate
range (Table 2).
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Table 1 Baseline demographics and disease characteristics by prior treatment
N None MPH-IR
once-daily
MPH-IR repeated MPH-MR Other, no
specification
Baseline demographics (n = 822)
Patients, n (%) 822 208 (25.30) 101 (12.29) 270 (32.84) 203 (24.70) 40 (4.87)
Male, n (%) 663 167 (25.19) 80 (12.07) 217 (32.73) 166 (25.04) 33 (4.98)
Mean (SD) age (years) 808 9.76 (2.74) 9.78 (2.25) 9.94 (2.40) 10.46 (2.29) 10.61 (2.60)
Mean (SD) height (cm) 764 143.15 (15.62) 143.30 (14.77) 142.81 (14.52) 145.73 (15.58) 144.22 (14.51)
Mean (SD) weight (kg) 786 38.32 (14.82) 37.34 (12.28) 37.79 (13.90) 38.37 (12.85) 37.10 (12.34)
Mean (SD) BMI (kg/m2) 758 18.13 (3.56) 17.74 (3.13) 18.01 (3.62) 17.71 (3.17) 17.47 (3.04)
ADHD diagnosis (n = 778)
F90.0: disturbance of activity/attention, n (%) 431 100 (52.08) 47 (52.22) 152 (57.58) 116 (58.88) 16 (45.71)
F90.1: hyperkinetic conduct disorder, n (%) 283 69 (35.94) 32 (35.56) 94 (35.61) 71 (36.04) 17 (48.57)
F90.8: other hyperkinetic disorders, n (%) 64 23 (11.98) 11 (12.22) 18 (6.82) 10 (5.08) 2 (5.71)
BMI body mass index, IR immediate release, MR modified release, MPH methylphenidate, SD standard deviation
Table 2 Summary of analysis of KINDL quality of life scores (on three different versions of the questionnaire) for patients and their parents
Quality of life rating scale N Assessment visit Main effect t test and effect size
Visit 1 Visit 3 t* Cohen’s d (Visit 1–Visit 3)
Mean (SD) Mean (SD)
Parent ratings (KINDL-P)
Total score 590 62.75 (13.34) 71.10 (11.71) -16.3 0.67
Physical wellbeing 600 71.83 (18.25) 78.77 (16.35) -9.1 0.37
Emotional wellbeing 600 67.55 (17.52) 74.77 (15.08) -10.3 0.42
Self esteem 600 54.94 (18.26) 63.50 (16.26) -11.6 0.47
Family 600 62.06 (19.42) 69.42 (16.90) -10.2 0.42
Friends 600 60.19 (20.99) 68.74 (17.85) -11.3 0.46
School 590 60.67 (18.56) 71.81 (16.28) -14.4 0.59
Patient ratings (age 6–11 years, KID-KINDL)
Total score 438 66.28 (13.37) 73.38 (11.66) -10.9 0.52
Physical wellbeing 445 74.08 (17.15) 78.93 (16.44) -5.4 0.26
Emotional wellbeing 445 71.66 (16.77) 77.02 (14.68) -6.4 0.30
Self esteem 445 58.10 (20.11) 65.88 (19.88) -7.4 0.35
Family 444 67.43 (20.12) 75.02 (16.05) -8.3 0.39
Friends 444 66.85 (21.49) 73.02 (18.91) -6.3 0.30
School 440 59.15 (22.01) 70.24 (18.06) -10.2 0.48
Patient ratings (age 12–17 years, KIDDO-KINDL)
Total score 152 65.63 (12.88) 71.69 (12.20) -6.2 0.51
Physical wellbeing 154 72.81 (17.54) 77.68 (16.45) -3.4 0.28
Emotional wellbeing 154 72.40 (16.18) 76.18 (14.85) -2.8 0.22
Self esteem 154 57.36 (18.78) 64.77 (18.90) -5.1 0.41
Family 154 66.25 (23.18) 73.17 (19.05) -4.2 0.34
Friends 154 68.14 (19.99) 72.63 (17.41) -3.2 0.25
School 152 55.98 (16.45) 65.21 (16.33) -6.7 0.54
Cohen’s d effect sizes are considered small (0.20 C d \ 0.50), medium (0.50 C d \ 0.80) or large (0.80 C d) [13]
SD standard deviation
* All effects are statistically significant at p \ 0.001
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There were no substantial differences between the
results of the KID-KINDL questionnaire and the KIDDO-
KINDL (12–17 years) version for the total score
(t = 0.350; p = 0.726) and all other scores (Table 2). The
KIDDO-KINDL total score averaged 65.6 at Visit 1 and
71.7 at Visit 3, which was a significant improvement
(p \ 0.001; Table 2). In analyses by prior treatment,
improvements were found in all subgroups, with the largest
effects for both parents’ and patients’ ratings seen in the
group with no prior pharmacotherapy (Fig. 1).
Treatment satisfaction
For patients with at least one post-baseline visit, both
parent- and patient-rated SAMS scores decreased from
Visit 1 to the last visit (Visit 2 or Visit 3), indicating an
improvement in satisfaction on medication with Equasym
XL compared with previous drug therapy (Table 3).
Mean (SD) scores decreased from 2.8 (1.1) to 2.4 (1.1)
points for parent ratings, and from 2.6 (1.0) to 2.3 (1.0)
points for patient ratings. Thus, both patients and their
parents rated therapy with Equasym XL as better than the
previous drug therapy.
Subgroup analyses by prior treatment showed that the
smallest improvement in patient satisfaction was found for
the group of patients who had been previously treated with
MPH-MR (difference in scores -0.13) and the greatest
improvement was in the ‘other’ subgroup (difference in
scores -0.70). By parental assessment, improvements over
previous MPH treatment were similar for MPH-MR, once-
daily MPH-IR and MPH-IR administered several times a
day (-0.34, -0.33 and -0.39, respectively) and greatest
for the ‘Other’ subgroup (–0.85).
Physician-rated adherence
The mean (SD) adherence score improved from 2.1 (1.2) to
1.5 (1.0) during the study, with the majority of patients
rated by their physician as ‘very good’ or ‘good’ at last
visit (Fig. 2a). Adherence during Equasym XL treatment
was frequently rated as superior to adherence during prior
treatment (Fig. 2b). A particular advantage was noted for
Equasym XL versus MPH-IR administered several times
per day, with 57.7% of the patients rated as having better
adherence with Equasym XL.
Physician-rated tolerability
Adverse events are reported elsewhere [15]. Treatment
with Equasym XL was generally well tolerated; a total of
26/822 evaluable patients (3.2%) discontinued treatment
due to adverse events.
At Visit 3, physicians rated the global tolerability of
Equasym XL as ‘very good’ in the majority (415/734;
56.5%) of the patients. ‘Good’ was the next most fre-
quent tolerability rating, for 270/734 (36.8%) patients,
with only 33/734 (4.5%) patients rated as having ‘mod-
erate’ tolerability and 16/734 (2.2%) patients as ‘poor’
(no assessment was provided for 88 patients). When
analysed by prior treatment, the main differences were
seen in the categories ‘very good’ and ‘good’ (Fig. 3).
Patients who were treated with MPH-MR prior to the
Fig. 1 Quality of life total scores (KINDL questionnaire, parent
ratings) during the study, by prior treatment. All comparisons are
significant at p B 0.001 (two-tailed test between KINDL total score at
Visit 1 versus total score at Visit 3). IR immediate release, MPH
methylphenidate, MR modified release
Table 3 Summary of analysis of satisfaction with medication scale scores for patients and their parents
Satisfaction with medication N Assessment visit Main effect MANOVA and effect size
Visit 1 Visit 2 Visit 3 F (t)* Cohen’s d (Visit 1–Visit 3)
Mean SD Mean SD Mean SD
Parent rating 484 2.80 1.07 2.55 1.04 2.41 1.07 23.2 0.31
Patient rating 468 2.59 0.96 2.34 0.96 2.27 0.98 22.5 0.38
ANOVA analysis of variance; SD standard deviation
* All effects are statistically significant at p \ 0.001
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study showed the highest ratings for the categories
‘moderate’ and ‘poor’.
Discussion
We report that patients with ADHD showed improvements
in QoL and satisfaction with medication during treatment
with once-daily Equasym XL in this large observational
study. Improvements were similar for both parent- and
patient-assessed outcomes. There were no signs that patient
tolerability of Equasym XL differed under routine care
conditions compared with the clinical trial setting.
In line with the emerging evidence showing that QoL
improves with effective treatment [14], parents scored total
QoL as 13.3% higher and patient-reported total QoL scores
were 10.8% higher during Equasym XL treatment com-
pared with before starting Equasym XL. On both parents’
and patients’ ratings, QoL improvements during the study
were greatest for the subgroup of patients who had not
received any prior treatment. Due to the potential for dis-
crepancies between parent and child reports, with parents
tending to rate their children with ADHD as having lower
QoL than the children themselves [14], it is generally
recommended that both perspectives are assessed to pro-
vide a comprehensive assessment [10, 25]. Poor parent–
child agreement in health-related QoL was reported in a
recent study [30], but another study showed improvement
in QoL in both children and their families, following a
change in MR formulation [6]. Our observations appear to
show a good concordance between patients and their par-
ents in terms of QoL and satisfaction outcomes, which
were rated as improved to a similar extent by both groups
(although statistical testing was not performed).
There is a general lack of consistency across studies in
the instruments that have been used to measure QoL,
which, together with variability in how QoL is defined,
makes cross-study, and cross-disease, comparisons difficult
[14]. However, the BELLA study also used the KINDL
questionnaire to assess QoL [32]. In that study, the mean
(SD) KINDL total score was 76.3 (10.1), as rated by par-
ents of children aged 7–17 years, and 73.0 (10.2) from self-
ratings of children and adolescents aged 11–17 years [32].
Comparison of OBSEER data (Table 2) with this reference
(a)
(b)
Fig. 2 a Mean ratings of adherence to treatment with Equasym XL,
as assessed by attending physicians, at last visit. n = 773; 49 missing
values. 1 very good, 6 fail. b Adherence to treatment with Equasym
XL compared with adherence to prior treatment. n = 553; 61
missing values. IR immediate release, MPH methylphenidate, MR
modified release
Fig. 3 Physician-rated global assessment of tolerability at Visit 3, by
prior treatment. n = 734; 88 missing values. IR immediate release,
MPH methylphenidate, MR modified release
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population showed that overall QoL approached normative
values after treatment with Equasym XL, although it
should be noted that this effect was not consistently seen
across all subscales, and that age groupings are not directly
comparable between the two studies.
According to physicians’ assessments, the tolerability of
treatment was rated ‘very good’ or ‘good’ in 93.3% of the
patients. Furthermore, both patients and their parents rated
therapy with Equasym XL as better than the previous
drug therapy. Specific reasons for this preference were not
investigated; however, it could be hypothesised that a
positive clinical response would increase the likelihood of
overall patient satisfaction with study treatment. Indeed,
adherence generally decreases when there is a limited
improvement in symptoms, or if adverse events occur [8].
Increased satisfaction should also have a positive impact
on adherence to therapy. In this study, adherence was
generally rated by physicians as ‘very good’ or ‘good’, and
was frequently rated as better than during prior treatment,
particularly for patients who had received MPH-IR dosed
several times per day. This supports previous studies
showing improved adherence with once-daily formulations
versus multiple daily doses of IR formulations [29].
Improved adherence may result from Equasym XL
meeting patient’s daily needs better than conventional
MPH preparations, because of factors such as its particular
pharmacokinetic profile [3] or greater ease of administra-
tion. Although adherence was rated subjectively by the
physician only, the results of the OBSEER study should be
an accurate reflection of the real-life situation compared
with controlled study populations in which adherence is
thought to be artificially high [1]. The long-term conse-
quences of medication non-adherence have not been
examined in ADHD, but it is generally believed that
maintaining good adherence to treatment regimens will
maximise efficacy outcomes. In a review of clinical trial
populations of both children and adults, mean non-adher-
ence rates of between 13.2 and 64% were found [1]. The
highest (64%) of these rates was seen 5 years after treat-
ment began, suggesting that non-adherence increases when
patients are followed for longer periods of time [9].
While the study design based on the routine care setting
is of clear value to clinical practice, as confirmed by pre-
vious ‘real-life’ studies in ADHD [19, 33], there were
several limitations to this study. As this was a non-ran-
domised, open-label trial without a control group, the raters
were not blinded to study treatment or dose. Patients with
low QoL on prior medications may be over-represented, as
this may have been a motivating factor for study partici-
pation, and this may limit the generalisability of the results.
In addition, KINDL data are only available for patients
aged from 8 years onwards, and not from age 6 years as
originally planned.
This study demonstrated that, compared with prior
therapy including MPH-MR preparations, once-daily
Equasym XL improves QoL and treatment satisfaction, as
assessed by both parents and patients under routine care
conditions. ADHD has a major impact on patient QoL, and
using treatment options that are accepted by patients may
represent an effective strategy to improve QoL. Such
observational studies should prompt the further investiga-
tion of the benefits of using drug treatment in terms of QoL
for patients and their families, and treatment satisfaction in
a real-life setting.
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